Beverly R Wuertz

Ms. Beverly R Wuertz

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JLJoseph E. De Larco
Joseph E. De Larco
BWBeverly R Wuertz
Beverly R Wuertz
LFLeo T. Furcht
Leo T. Furcht
In the last decade, several groups have shown a direct correlation between the inappropriate or ectopic release of interleukin (IL)-8 by tumor cells in vitro and their growth and metastatic potential using in vivo models of tumor growth. IL-8 is a potent neutrophil chemoattractant. Neutrophils, as “early responders” to wounds and infections, release enzymes to remodel the extracellular matrix of the tissues through which they migrate to reach the site of the wound or infection. It is proposed that the host’s cellular response to IL-8 released by tumor cells enhances angiogenesis and contributes to tumor growth and progression. The activities released by the responding neutrophils could serve as enablers of tumor cell migration through the extracellular matrix, helping them enter the vasculature and journey to new, metastatic sites. The reactive oxygen species produced by neutrophilic oxidases to kill invading organisms have the potential to interact with tumor cells to attenuate their apoptotic cascade and increase their mutational rate. It is proposed that the increase in metastatic potential of tumors ectopically releasing IL-8 is, in part, attributable to their ability to attract neutrophils. Discussed here are possible mechanisms by which the neutrophils responding to ectopic IL-8 contribute to the in vivo growth, progression, and metastatic potential of tumor cells. Possible targets are also presented for the development of therapies to attenuate the effects of the ectopic IL-8 release by tumor cells.

1 February 2001 in The American Journal of Pathology
Verified
Journal Article
Closed access
JLJoseph E. De Larco
Joseph E. De Larco
BWBeverly R Wuertz
Beverly R Wuertz
KRKaren A. Rosner
Karen A. Rosner
SESteven A. Erickson
Steven A. Erickson
DGDavid E. Gamache
David E. Gamache
LFLeo T. Furcht
Leo T. Furcht

8 September 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
JGJ.Silvio Gutkind
J.Silvio Gutkind
AMAlfredo A. Molinolo
Alfredo A. Molinolo
XWxingyu wu
xingyu wu
ZWZhiyong Wang
Zhiyong Wang
DNDaniela Nachmanson
Daniela Nachmanson
ESEva Szabo
Eva Szabo
BACKGROUND: The aberrant activation of the PI3K/mTOR signaling circuitry is one of the most frequently dysregulated signaling events in head and neck squamous cell carcinoma (HNSCC). Here, we conducted a single-arm, open-label phase IIa clinical trial in individuals with oral premalignant lesions (OPLs) to explore the potential of metformin to target PI3K/mTOR signaling for HNSCC prevention. METHODS: Individuals with OPLs, but who were otherwise healthy and without diabetes, underwent pretreatment and posttreatment clinical exam and biopsy. Participants received metformin for 12 weeks (week 1, 500 mg; week 2, 1000 mg; weeks 3–12, 2000 mg daily). Pretreatment and posttreatment biopsies, saliva, and blood were obtained for biomarker analysis, including IHC assessment of mTOR signaling and exome sequencing. RESULTS: Twenty-three participants were evaluable for response. The clinical response rate (defined as a ≥50% reduction in lesion size) was 17%. Although lower than the proposed threshold for favorable clinical response, the histological response rate (improvement in histological grade) was 60%, including 17% complete responses and 43% partial responses. Logistic regression analysis revealed that when compared with never smokers, current and former smokers had statistically significantly increased histological responses ( P = 0.016). Remarkably, a significant correlation existed between decreased mTOR activity (pS6 IHC staining) in the basal epithelial layers of OPLs and the histological ( P = 0.04) and clinical ( P = 0.01) responses. CONCLUSION: To our knowledge this is the first phase II trial of metformin in individuals with OPLs, providing evidence that metformin administration results in encouraging histological responses and mTOR pathway modulation, thus supporting its further investigation as a chemopreventive agent. TRIAL REGISTRATION: NCT02581137 FUNDING: NIH contract HHSN261201200031I, grants R01DE026644 and R01DE026870

17 November 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JLJoseph E. De Larco
Joseph E. De Larco
BWBeverly R Wuertz
Beverly R Wuertz
DYDouglas Yee
Douglas Yee
BRBrenda L. Rickert
Brenda L. Rickert
LFLeo T. Furcht
Leo T. Furcht
Previously, we have shown that a strong correlation exists between the metastatic potential of breast carcinoma cell lines and their ectopic expression of IL-8. The undifferentiated, highly metastatic cell lines with high metastatic potential produce much more IL-8 than their differentiated lower metastatic counterparts. After eliminating the possibility that transcription factor activity was responsible for differences in IL-8 release, we examined the IL-8 gene for possible epigenetic modifications. Here, we report an aberrant methylation pattern that may be responsible for the differences in IL-8 release between the high and low metastatic cell lines. We determined that none of the deoxycytidylate-phosphate-deoxyguanylate (CpG) sites in the reported IL-8 promoter were methylated in either cell type. Much further upstream in the IL-8 gene, two CpG sites were identified that are differentially methylated. These two sites were fully methylated in the high metastatic cell lines, which produce large quantities of IL-8 and remain unmethylated in the low metastatic cell lines where the IL-8 gene is relatively silent. The DNA methylation results presented here differ from the common epigenetic paradigm in which methylation of promoter CpG islands silences gene expression, suggesting that there are additional epigenetic control mechanisms that as yet have not been fully appreciated or explored.

1 March 2008 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
DPDiego Preciado
Diego Preciado
JLJezhin Lin
Jezhin Lin
BWBeverly R Wuertz
Beverly R Wuertz
MRMary Rose
Mary Rose

1 April 2001
Verified
Journal Article
Closed access
JLJ E De Larco
J E De Larco
BWBeverly R Wuertz
Beverly R Wuertz
JMJ C Manivel
J C Manivel
LFL T Furcht
L T Furcht